| Title: |
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data |
| Authors: |
Strutton David R; Farkouh Raymond A; Rubin Jaime L; McGarry Lisa J; Loiacono Paul M; Klugman Keith P; Pelton Steven I; Gilmore Kristen E; Weinstein Milton C |
| Source: |
BMC Infectious Diseases, Vol 12, Iss 1, p 175 (2012) |
| Publisher Information: |
BMC |
| Publication Year: |
2012 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
Pneumococcal conjugate vaccine; Catch-up vaccination; Pneumococcal; PCV13; 13-valent; Infectious and parasitic diseases; RC109-216 |
| Description: |
Background Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%. Methods This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant. Results Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program. Conclusions Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
http://www.biomedcentral.com/1471-2334/12/175; https://doaj.org/toc/1471-2334; https://doaj.org/article/a341dcc892f94c8dbf164d2d23b5a9e8 |
| DOI: |
10.1186/1471-2334-12-175 |
| Availability: |
https://doi.org/10.1186/1471-2334-12-175; https://doaj.org/article/a341dcc892f94c8dbf164d2d23b5a9e8 |
| Accession Number: |
edsbas.483C006E |
| Database: |
BASE |